KIDS Stock Analysis: Orthopediatrics | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 692m USD | 12M Return: 33.9% | US68752L1008 | Charts, Fundamentals & Technical Analysis

Trauma Implants, Spinal Deformity, Sports Medicine, Bracing
Total Rating 52
Safety 77
Buy Signal 0.59
Medical Devices
Industry Rotation: +6.1
Market Cap: 692M
Avg Turnover: 4.87M
Risk 3d forecast
Volatility47.7%
VaR 5th Pctl8.18%
VaR vs Median4.04%
Reward TTM
Sharpe Ratio0.78
Rel. Str. IBD88.1
Rel. Str. Peer Group72.9
Character TTM
Beta0.888
Beta Downside0.673
Hurst Exponent0.470
Drawdowns 3y
Max DD62.13%
CAGR/Max DD-0.18
CAGR/Mean DD-0.29
EPS (Earnings per Share) EPS (Earnings per Share) of KIDS over the last years for every Quarter: "2021-06": -0.11, "2021-09": -0.15, "2021-12": -0.24, "2022-03": -0.3, "2022-06": -0.17, "2022-09": -0.05, "2022-12": -0.35, "2023-03": -0.29, "2023-06": -0.19, "2023-09": -0.13, "2023-12": -0.23, "2024-03": -0.34, "2024-06": -0.23, "2024-09": -0.18, "2024-12": -0.29, "2025-03": -0.39, "2025-06": -0.11, "2025-09": -0.24, "2025-12": -0.26, "2026-03": -0.42, "2026-06": -0.26,
Last SUE: 0.78
Qual. Beats: 0
Revenue Revenue of KIDS over the last years for every Quarter: 2021-06: 26.695, 2021-09: 25.079, 2021-12: 24.813, 2022-03: 23.417, 2022-06: 32.928, 2022-09: 34.95, 2022-12: 30.994, 2023-03: 31.588, 2023-06: 39.559, 2023-09: 39.972, 2023-12: 37.613, 2024-03: 44.685, 2024-06: 52.802, 2024-09: 54.573, 2024-12: 52.667, 2025-03: 52.411, 2025-06: 61.082, 2025-09: 61.25, 2025-12: 61.605, 2026-03: 59.362, 2026-06: 70.508,
Rev. CAGR: 23.71%
Rev. Trend: 98.2%
Last SUE: 2.78
Qual. Beats: 1

Warnings

Interest Coverage Ratio Critical

Tailwinds

Supp Ema8
Rs Leader
Tailwind

Seasonality

Not enough history
Description: KIDS Orthopediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) is a medical device company that designs, develops, and markets anatomically appropriate implants, instruments, and braces specifically for children with orthopedic conditions. Its product portfolio spans three main categories: pediatric trauma and deformity correction, scoliosis procedures, and sports medicine and other products, featuring a wide range of branded systems and platforms such as PediLoc, RESPONSE Spine, the Fassier-Duval Telescopic Intramedullary System, and the Boston Brace 3D. The company serves the pediatric orthopedic market, including pediatric orthopedic surgeons and caregivers, in both the United States and international markets. Founded in 2006 and headquartered in Warsaw, Indiana, OrthoPediatrics is a small-cap ($501M USD) health care supplies company that listed on NASDAQ in October 2017.

OrthoPediatrics operates in a specialized niche within the broader orthopedic device industry, which is largely dominated by large-cap manufacturers focused on adult populations. As a pure-play pediatric orthopedic company, its business model depends on surgeon relationships, recurring procedure-based revenue, and ongoing regulatory clearances and approvals from the U.S. Food and Drug Administration (FDA) for new and modified devices. Its broad product portfolio, which spans implants, instruments, and bracing, allows it to serve a wide range of procedures and patient ages within childrens orthopedics.

Headlines to Watch Out For
  • Scoliosis and trauma segment revenue drives double-digit domestic growth
  • Operating losses persist as salesforce expansion and acquisitions pressure margins
  • International expansion lifts geographic revenue mix with European momentum
Piotroski VR-10 (Strict) 2.0
Net Income: -39.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA 7.12 > 1.0
NWC/Revenue: 79.00% < 20% (prev 99.23%; Δ -20.23% < -1%)
CFO/TA 0.01 > 3% & CFO 7.41m > Net Income -39.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.78 > 1.5 & < 3
Outstanding Shares: last quarter (23.9m) vs 12m ago 2.24% < -2%
Gross Margin: 73.65% > 18% (prev 71.54%; Δ 2.11% > 0.5%)
Asset Turnover: 49.80% > 50% (prev 43.83%; Δ 5.97% > 0%)
Interest Coverage Ratio: -2.72 > 6 (EBIT TTM -22.8m / Interest Expense TTM 8.38m)
Altman Z'' 2.54
A: 0.39 (Total Current Assets 252.5m - Total Current Liabilities 52.9m) / Total Assets 511.4m
B: -0.57 (Retained Earnings -293.1m / Total Assets 511.4m)
C: -0.04 (EBIT TTM -22.8m / Avg Total Assets 507.5m)
D: 2.05 (Book Value of Equity 343.6m / Total Liabilities 167.8m)
Altman-Z'' = 2.54 = A
Beneish M -2.92
DSRI: 0.99 (Receivables 61.0m/53.8m, Revenue 252.7m/220.7m)
GMI: 0.97 (GM 71.54% / 73.65%)
AQI: 1.07 (AQ_t 0.41 / AQ_t-1 0.38)
SGI: 1.14 (Revenue 252.7m / 220.7m)
TATA: -0.09 (NI -39.7m - CFO 7.41m) / TA 511.4m)
Beneish M = -2.92 (Cap -4..+1) = A
What is the price of KIDS shares?

As of August 22, 2026, the stock is trading at USD 25.65 with a total of 257,632 shares traded. Over the past week, the price has changed by +3.43%, over one month by +31.61%, over three months by +39.18% and over the past year by +33.94%.

Current recommended Stop Loss: 24.30 (which is 5.3% or 1.3 ATR below the current price).

Is KIDS a buy, sell or hold?

Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.

  • StrongBuy: 3
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KIDS price?
Analysts Target Price 26.7 4%
Orthopediatrics (KIDS) - Fundamental Data Overview as of 21 August 2026
Market Cap USD = 691.9m (691.9m USD * 1.0 USD.USD)
P/S = 2.7378
P/B = 1.9392
Revenue TTM = 252.7m USD
EBIT TTM = -22.8m USD
EBITDA TTM = -447k USD
Long Term Debt = 99.5m USD (from longTermDebt, last quarter)
Short Term Debt = 172k USD (from shortTermDebt, last quarter)
Debt = 99.9m USD (corrected: LT Debt 99.5m + ST Debt 172k) + Leases 320k
Net Debt = 54.1m USD (calculated: Debt 99.9m - CCE 45.9m)
Enterprise Value = 746.0m USD (691.9m + Debt 99.9m - CCE 45.9m)
Interest Coverage Ratio = -2.72 (Ebit TTM -22.8m / Interest Expense TTM 8.38m)
EV/FCF = -406.5x (Enterprise Value 746.0m / FCF TTM -1.83m)
FCF Yield = -0.25% (FCF TTM -1.83m / Enterprise Value 746.0m)
FCF Margin = -0.73% (FCF TTM -1.83m / Revenue TTM 252.7m)
Net Margin = -15.72% (Net Income TTM -39.7m / Revenue TTM 252.7m)
Gross Margin = 73.65% ((Revenue TTM 252.7m - Cost of Revenue TTM 66.6m) / Revenue TTM)
Gross Margin QoQ = 74.27% (prev 73.09%)
Tobins Q-Ratio = 1.46 (Enterprise Value 746.0m / Total Assets 511.4m)
Interest Expense / Debt = 8.39% (Interest Expense 8.38m / Debt 99.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -18.0m (EBIT -22.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.78 (Total Current Assets 252.5m / Total Current Liabilities 52.9m)
Debt / Equity = 0.29 (Debt 99.9m / totalStockholderEquity, last quarter 343.6m)
 Debt / EBITDA = -121.0 (out of range, set to none) (Net Debt 54.1m / EBITDA -447k)
 Debt / FCF = -29.47 (negative FCF - burning cash) (Net Debt 54.1m / FCF TTM -1.83m)
 Total Stockholder Equity = 344.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.83% (Net Income -39.7m / Total Assets 511.4m)
RoE = -11.53% (Net Income TTM -39.7m / Total Stockholder Equity 344.6m)
RoCE = -5.13% (EBIT -22.8m / Capital Employed (Equity 344.6m + L.T.Debt 99.5m))
 RoIC = -4.03% (negative operating profit) (NOPAT -18.0m / Invested Capital 446.1m)
 WACC = 8.80% (E(691.9m)/V(791.9m) * Re(9.11%) + D(99.9m)/V(791.9m) * Rd(8.39%) * (1-Tc(0.21)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.86 | Cagr: 2.01%
 [DCF] Fair Price = unknown (Cash Flow -1.83m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.78 | # QB: 0
Revenue Correlation: 98.16 | Revenue CAGR: 23.71% | SUE: 2.78 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.21 | Chg30d=-26.47% | Revisions=-50% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.09 | Chg30d=-3.88% | Revisions=-17% | GrowthEPS=-9.2% | GrowthRev=+13.0%
EPS next Year (2027-12-31): EPS=-0.71 | Chg30d=-4.41% | Revisions=+17% | GrowthEPS=+35.0% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: -25% (up=3, down=6)